Community-acquired pneumonia - clinical features

Community-acquired pneumonia (CAP) presents with diverse clinical features, ranging from typical symptoms like fever, cough, and chest pain to atypical presentations with more insidious onset and non-respiratory complaints. Accurate diagnosis requires a thorough assessment of risk factors, clinical presentation, and appropriate diagnostic testing, while treatment involves prompt initiation of empiric antibiotics based on severity and local resistance patterns.

Definition and Scope: Community-Acquired Pneumonia (CAP) is defined as pneumonia that develops in a person who is not hospitalized or residing in a long-term care facility (e.g., nursing home) for 14 days or more before the onset of symptoms. This distinguishes it from hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), which have different etiologies and often involve more resistant organisms. Understanding this distinction is crucial for appropriate treatment strategies. CAP is a significant cause of morbidity and mortality worldwide, particularly in older adults, young children, and individuals with underlying health conditions. The incidence of CAP varies depending on geographical location, season, and age group, but it remains a frequent reason for seeking medical care. Historically, before the advent of antibiotics, CAP was a leading cause of death.

Common Etiological Agents: While various pathogens can cause CAP, Streptococcus pneumoniae remains the most common bacterial culprit. Other significant bacterial causes include Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Moraxella catarrhalis. Viral etiologies are also common, particularly influenza viruses (A and B), respiratory syncytial virus (RSV), adenovirus, and rhinovirus. Increasingly, atypical bacteria and viral infections are being recognized as significant contributors to CAP, necessitating diagnostic testing beyond traditional bacterial cultures. The relative frequency of these pathogens can shift depending on the season and local epidemiological factors. Understanding the local patterns of pathogen prevalence is essential for empirical antibiotic selection.

Typical Symptoms: "Typical" CAP often presents with a constellation of acute symptoms that include: sudden onset of fever (often high-grade), productive cough (producing purulent or mucopurulent sputum), pleuritic chest pain (sharp pain that worsens with breathing), dyspnea (shortness of breath), and sometimes, rigors (severe chills). Physical examination may reveal signs of consolidation, such as dullness to percussion, increased tactile fremitus, and bronchial breath sounds. However, these classic signs may be absent, particularly in older adults or individuals with underlying lung disease. It is crucial to remember that a typical presentation does not guarantee a specific pathogen; it simply raises the likelihood of bacterial infection. Prompt evaluation and appropriate investigations are necessary to confirm the diagnosis and guide treatment.

Atypical Symptoms and Presentations: "Atypical" CAP often presents with more insidious symptoms, such as gradual onset of dry cough, headache, myalgia (muscle aches), fatigue, and sore throat. Fever may be low-grade or absent. Gastrointestinal symptoms, such as nausea, vomiting, and diarrhea, are also more common with atypical pneumonias. Radiographic findings may differ from typical pneumonia, often showing patchy infiltrates or interstitial patterns rather than lobar consolidation. Common causes of atypical pneumonia include Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila. The term "atypical" refers to the clinical presentation rather than the causative organism being unusual. Atypical presentations require different antibiotic coverage compared to typical bacterial pneumonias.

Risk Factors: Several factors increase the risk of developing CAP. These include: advanced age (especially >65 years), chronic underlying diseases (e.g., COPD, asthma, heart failure, diabetes, chronic kidney disease), immunosuppression (e.g., HIV infection, organ transplant recipients, chemotherapy), smoking, alcohol abuse, and recent upper respiratory tract infection. Understanding these risk factors is crucial for identifying individuals who are at higher risk for severe disease and complications. Prophylactic measures, such as vaccination against influenza and pneumococcal disease, are particularly important in high-risk individuals. Furthermore, addressing modifiable risk factors, such as smoking cessation and alcohol moderation, can significantly reduce the risk of developing CAP.

Clinical Assessment Tools: CURB-65 and Pneumonia Severity Index (PSI): The CURB-65 and PSI are scoring systems used to assess the severity of CAP and guide decisions regarding inpatient versus outpatient management. CURB-65 assesses: Confusion, Urea >7 mmol/L, Respiratory rate ≥30 breaths/min, Blood pressure (systolic <90 mmHg or diastolic ≤60 mmHg), and age ≥65 years. Each factor is assigned 1 point, with higher scores indicating greater severity and need for hospitalization. The PSI is a more complex scoring system that incorporates numerous demographic, clinical, and laboratory variables to stratify patients into risk classes. While both tools are helpful, they should be used in conjunction with clinical judgment. These tools help avoid unnecessary hospitalizations and ensure that patients receive the appropriate level of care based on their individual risk profile.

Diagnostic Investigations: The cornerstone of CAP diagnosis is chest radiography (CXR). CXR helps confirm the presence of pulmonary infiltrates and rule out other conditions. Sputum cultures and Gram stains can help identify the causative organism, but their utility is limited by poor sensitivity and specificity. Blood cultures should be obtained in patients with severe CAP or those requiring hospitalization. Urinary antigen testing for Streptococcus pneumoniae and Legionella pneumophila provides rapid diagnostic information. PCR-based assays for respiratory viruses are increasingly used to identify viral etiologies. Arterial blood gas analysis can assess the severity of hypoxemia and guide oxygen therapy. The choice of diagnostic tests depends on the clinical context, the severity of illness, and local laboratory availability.

Common Misconceptions: A common misconception is that all pneumonias are caused by bacteria and require antibiotics. Viral pneumonias are frequently underdiagnosed and may resolve spontaneously without antibiotic treatment. Another misconception is that a normal CXR rules out pneumonia. In some cases, particularly early in the course of the illness or in dehydrated patients, CXR findings may be subtle or absent. Another misunderstanding involves the utility of sputum cultures. It is crucial to obtain sputum samples before initiating antibiotic therapy and ensure the sample is of adequate quality (i.e., contains few epithelial cells and numerous neutrophils). Lastly, there's a false belief that all patients with CAP require hospitalization. Risk assessment tools like CURB-65 and PSI can help identify patients who can be safely managed as outpatients.

Complications of CAP: CAP can lead to several complications, especially in vulnerable populations. These include: Empyema (pus accumulation in the pleural space), lung abscess (localized area of necrosis within the lung), bacteremia (presence of bacteria in the bloodstream), sepsis (life-threatening organ dysfunction caused by a dysregulated host response to infection), acute respiratory distress syndrome (ARDS), and respiratory failure. Early recognition and prompt management of these complications are crucial for improving patient outcomes. Patients with underlying comorbidities, severe disease, or delayed treatment are at higher risk for developing complications. Monitoring for signs of clinical deterioration and escalating care as needed are essential components of CAP management.

Treatment Principles: The main goal of CAP treatment is to eradicate the causative pathogen and prevent complications. Empiric antibiotic therapy should be initiated promptly, guided by local antibiotic resistance patterns and patient-specific risk factors. Outpatient treatment typically involves oral antibiotics, such as macrolides (e.g., azithromycin, clarithromycin) or doxycycline, or a respiratory fluoroquinolone (e.g., levofloxacin, moxifloxacin) or beta-lactam plus a macrolide. Inpatient treatment often involves intravenous antibiotics, such as beta-lactam/beta-lactamase inhibitor combinations (e.g., ampicillin-sulbactam, piperacillin-tazobactam) or cephalosporins (e.g., ceftriaxone, cefotaxime), often in combination with a macrolide or respiratory fluoroquinolone. The duration of antibiotic therapy typically ranges from 5 to 7 days, depending on the severity of illness and clinical response. Supportive care, including oxygen therapy, fluid management, and pain relief, is also crucial.

Prevention Strategies: Preventing CAP is paramount, especially in vulnerable populations. Vaccination against Streptococcus pneumoniae (pneumococcal vaccines: PCV13 and PPSV23) and influenza viruses is highly effective in reducing the incidence and severity of CAP. Smoking cessation is crucial, as smoking damages the respiratory tract and increases susceptibility to infection. Good hygiene practices, such as frequent handwashing and avoiding close contact with sick individuals, can help prevent the spread of respiratory pathogens. Addressing underlying health conditions and optimizing immune function are also important preventative measures. Public health campaigns promoting vaccination and healthy lifestyles can significantly reduce the burden of CAP.

Browse public study notes